Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-09 |
2024-03 |
-0.81 |
-0.79 |
0.02 |
2.47% |
2024-02-28 |
2023-12 |
-0.54 |
-0.79 |
-0.25 |
-46.30% |
2024-02-28 |
2023-12 |
-0.54 |
N/A |
N/A |
N/A |
2023-11-08 |
2023-09 |
-0.76 |
-0.71 |
0.05 |
6.58% |
2023-11-08 |
2023-09 |
-0.76 |
N/A |
N/A |
N/A |
2023-08-08 |
2023-06 |
-0.84 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-08-08 |
Credit Suisse |
Upgrade |
Outperform |
Outperform |
2023-08-08 |
Chardan Capital |
Upgrade |
Buy |
Buy |
2023-08-08 |
Needham |
Upgrade |
Buy |
Buy |
2023-05-21 |
Evercore ISI Group |
Upgrade |
In-Line |
Outperform |
2023-05-16 |
Needham |
Upgrade |
Buy |
Buy |
2023-05-10 |
Wells Fargo |
Upgrade |
Overweight |
Overweight |
Date |
Name |
Relation |
Quantity |
Description |
2020-06-15 |
ALEXANDRIA VENTURE INVESTMENTS, L.L.C |
Beneficial Owner of more than 10% of a Class of Security |
502.37K |
Conversion of Exercise of derivative security |
2024-05-06 |
BOYCE SARAH |
Chief Executive Officer |
112.12K |
Sale |
2020-06-15 |
CORMORANT ASSET MANAGEMENT ,L.P |
Unknown |
0.00 |
Purchase |
2020-06-15 |
ELI LILLY & CO |
Beneficial Owner of more than 10% of a Class of Security |
2.17M |
Conversion of Exercise of derivative security |
2024-01-21 |
FLANAGAN W MICHAEL PH.D. |
Chief Technology Officer |
35.87K |
Sale |
2024-05-19 |
LEVIN ARTHUR A |
Director |
268.70K |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
FMR, LLC |
10.62M |
117.81M |
14.34% |
2023-06-29 |
RTW Investments LP |
6.69M |
74.19M |
9.03% |
2023-06-29 |
Price (T.Rowe) Associates Inc |
6.68M |
74.13M |
9.02% |
2023-06-29 |
RA Capital Management, L.P. |
6.42M |
71.16M |
8.66% |
2023-06-29 |
State Street Corporation |
6.19M |
68.64M |
8.35% |
2023-06-29 |
Blackrock Inc. |
5.76M |
63.86M |
7.77% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-08-30 |
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF |
4.62M |
34.91M |
6.23% |
2023-06-29 |
Price (T.Rowe) New Horizons Fund |
3.36M |
37.23M |
4.53% |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
2.38M |
26.40M |
3.21% |
2023-08-30 |
Fidelity Growth Company Fund |
2.01M |
15.19M |
2.71% |
2023-08-30 |
iShares Russell 2000 ETF |
1.60M |
12.08M |
2.16% |
2023-06-29 |
Price (T.Rowe) Health Sciences Fund |
1.50M |
16.59M |
2.02% |